Quick Answer
Evommune, Inc. reported Operating Income Loss of -$81.07 million for the year ending 2025.
- Evommune, Inc. showed a decrease of -15.8% in Operating Income Loss from 2024 to 2025.
- This data is from Evommune, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: -$81.07 million | Fiscal year 2024: -$70.01 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: